Inclusion Criteria:

- Histologic or cytologic diagnosis of prostate carcinoma.

- Subject must have progressive metastatic prostate cancer despite adequate medical or
surgical castration therapy. Furthermore, if applicable, medical castration must be
maintained for the duration of the protocol.

- Serum testosterone < 50 ng/ml.

- Subjects who have received anti-androgen therapy with a resulting PSA decline must
demonstrate progression following discontinuation of anti-androgen therapy.

- Subjects capable of fathering children must agree to use an effective method of
contraception for the duration of the trial.

- Must have previously received docetaxel for prostate cancer

- ECOG performance status 0-2

- Willing and able to give informed consent

Exclusion Criteria:

- Platelet count <100,000/mm3

- Absolute neutrophil count (ANC) <1,500/mm3

- Hemoglobin < 8 g/dL

- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 x upper limit
of normal

- Bilirubin (total) >2 x upper limit of normal. Subjects with known Gilbert's syndrome
are eligible if direct bilirubin is within normal limits

- For subjects with serum creatinine > 1.5 x ULN, calculated creatinine clearance < 30
ml/min are excluded; subjects meeting this exclusion criterion are eligible if a
measured clearance is > 30 ml/min

- Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or
hematological organ systems which might preclude completion of this study or
interfere with determination of causality of any adverse effects experienced in this
study

- Prior investigational therapy within 4 weeks of treatment. Furthermore, other
investigational anti-cancer therapy is not permitted during the treatment phase.

- Grade > 1 peripheral neuropathy